Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
about
Meningococcal conjugate vaccines.Stability of PorA during a meningococcal disease epidemic.Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults.The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.Neisseria meningitidis: biology, microbiology, and epidemiology.Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvacImmunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assayChallenges and progress in the development of a serogroup B meningococcal vaccine.New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers.Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.Neisseria meningitidis B vaccines: recent advances and possible immunization policies.Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine.Neisserial outer membrane vesicles bind the coinhibitory receptor carcinoembryonic antigen-related cellular adhesion molecule 1 and suppress CD4+ T lymphocyte function.Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes.Neisseria meningitidis PorA variable regions: rapid detection of P1.7 and P1.19 variants by PCR.
P2860
Q30341333-A0FAA0A3-2EA3-420A-B994-EF14B66E15E3Q33825026-17BEA9C9-89AA-41A0-A2B3-E983F6F8ECF4Q34150340-2E8F071A-E99F-4055-A1A4-8ADE26AC53ABQ34601395-D6D6D857-A42C-476C-B06D-303A1A0F7CA9Q34632986-DF77D7C0-10FD-4BC6-ADD5-D0DD7677C413Q34975624-16C0EDC3-5743-43A1-ADA9-CE44BD860428Q35635880-9D0C4E27-18F8-4786-9816-58F61F24F8CCQ35946901-1BE2F10F-4309-402D-B158-2FAC530128FAQ36313615-778204F5-4323-48BF-B5A8-5D3CBD4667D4Q37503243-79A1ED5E-F62F-414E-AD1B-11993D510BBAQ37690815-06330003-19CA-4B04-833C-F52946C8EBAAQ37857249-38BFAD19-44BA-4D03-85AE-1573A8318C1DQ38183156-CA8C60BC-1F10-42D2-9B2D-67AC7A57F2BBQ40168476-74C4F00E-F82C-4BEF-9E40-7214A1070613Q42413093-DAC7C564-8FD6-4E15-8A08-BDCB3830F6B6Q42744347-B3477111-0B98-4810-8875-10D8042FDA0BQ43676398-C3509950-E2D6-437B-BDD1-5E00980D2136
P2860
Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Cross-reactivity of antibodies ...... uter membrane vesicle vaccine.
@ast
Cross-reactivity of antibodies ...... uter membrane vesicle vaccine.
@en
Cross-reactivity of antibodies ...... uter membrane vesicle vaccine.
@nl
type
label
Cross-reactivity of antibodies ...... uter membrane vesicle vaccine.
@ast
Cross-reactivity of antibodies ...... uter membrane vesicle vaccine.
@en
Cross-reactivity of antibodies ...... uter membrane vesicle vaccine.
@nl
prefLabel
Cross-reactivity of antibodies ...... uter membrane vesicle vaccine.
@ast
Cross-reactivity of antibodies ...... uter membrane vesicle vaccine.
@en
Cross-reactivity of antibodies ...... uter membrane vesicle vaccine.
@nl
P2093
P2860
P1476
Cross-reactivity of antibodies ...... uter membrane vesicle vaccine.
@en
P2093
Keijzers WC
Kuipers AJ
Vermont CL
de Groot R
van Alphen L
van Dijken HH
van Limpt CJ
van den Dobbelsteen GP
van der Ende A
P2860
P304
P356
10.1128/IAI.71.4.1650-1655.2003
P407
P577
2003-04-01T00:00:00Z